CM
IMNM icon

Caption Management’s Immunome IMNM Stock Holding History

Caption Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,500
Closed -$161K – 1776
2025
Q4 		$161K Sell
7,500
-1,028,200
-99% -$18M ﹤0.01% 1408
2025
Q3 		$12.1M Buy
+1,035,700
New +$10.3M 0.09% 232
2025
Q2 		– Sell
-750,000
Closed -$5.05M – 1671
2025
Q1 		$5.05M Buy
+750,000
New +$7.2M 0.05% 390

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Caption Management's IMNM Position: Q1 2026 in Review

Caption Management sold out of Immunome (IMNM) in Q1 2026, closing a stake of 5,300 shares — an estimated $114K sold.

Caption Management first reported a position in IMNM in Q3 2024 and held it in 4 quarters. The position peaked at $12.2M in Q3 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Caption Management reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 5,300 Immunome shares in Q1 2026, an estimated $114K.
  • Caption Management first reported a position in Immunome in Q3 2024 and held it in 4 quarters.
  • Caption Management's Immunome position peaked at $12.2M in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.